B
Bruce G. Haffty
Researcher at Rutgers University
Publications - 574
Citations - 26182
Bruce G. Haffty is an academic researcher from Rutgers University. The author has contributed to research in topics: Breast cancer & Radiation therapy. The author has an hindex of 74, co-authored 547 publications receiving 23718 citations. Previous affiliations of Bruce G. Haffty include University of Texas MD Anderson Cancer Center & University of Medicine and Dentistry of New Jersey.
Papers
More filters
Journal ArticleDOI
Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial
Judy C. Boughey,Vera J. Suman,Elizabeth A. Mittendorf,Gretchen M. Ahrendt,Lee G. Wilke,Bret Taback,A. Marilyn Leitch,Henry Mark Kuerer,Monet Bowling,Teresa S. Flippo-Morton,David R. Byrd,David W. Ollila,Thomas B. Julian,Sarah A. McLaughlin,Linda M. McCall,W. Fraser Symmans,Huong T. Le-Petross,Bruce G. Haffty,Thomas A. Buchholz,Heidi Nelson,Kelly K. Hunt +20 more
TL;DR: The application of SLN surgery for staging the axilla following chemotherapy for women who initially had node-positive cN1 breast cancer is unclear because of high false-negative results reported in previous studies as mentioned in this paper.
Journal ArticleDOI
Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer
Bruce G. Haffty,Qifeng Yang,Michael Reiss,Thomas Kearney,Susan A. Higgins,Joanne B. Weidhaas,Lyndsay Harris,Willam Hait,Deborah Toppmeyer +8 more
TL;DR: Patients classified as triple negative breast cancers have a poor prognosis, however, there was no evidence that these patients are at higher risk for local relapse after conservative surgery and radiation.
Journal ArticleDOI
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
Peter Bouwman,Amal Aly,José M. Escandell,Mark Pieterse,Jirina Bartkova,Hanneke van der Gulden,Sanne Hiddingh,Maria Thanasoula,Atul Kulkarni,Qifeng Yang,Bruce G. Haffty,Johanna Tommiska,Carl Blomqvist,Ronny Drapkin,David J. Adams,Heli Nevanlinna,Jiri Bartek,Madalena Tarsounas,Shridar Ganesan,Jos Jonkers +19 more
TL;DR: This work identifies p53-binding protein 1 (53BP1) as an essential factor for sustaining the growth arrest induced by Brca1 deletion, and finds reduced 53BP1 expression in subsets of sporadic triple-negative and BRCA-associated breast cancers, indicating the potential clinical implications of these findings.
Journal ArticleDOI
Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO).
Benjamin Smith,Benjamin Smith,Douglas W. Arthur,Thomas A. Buchholz,Bruce G. Haffty,Carol A. Hahn,Patricia H. Hardenbergh,Thomas B. Julian,Lawrence B. Marks,Dorin A. Todor,Frank A. Vicini,Timothy J. Whelan,Julia White,Jennifer Y. Wo,Jay R. Harris +14 more
TL;DR: This consensus statement is intended to provide guidance regarding the use ofAPBI outside of a clinical trial and to serve as a framework to promote additional clinical investigations into the optimal role of APBI in the treatment of breast cancer.
Journal ArticleDOI
Molecular Classification Identifies a Subset of Human Papillomavirus–Associated Oropharyngeal Cancers With Favorable Prognosis
Paul M. Weinberger,Ziwei Yu,Bruce G. Haffty,Diane Kowalski,Malini Harigopal,Janet L. Brandsma,Clarence T. Sasaki,John K. Joe,Robert L. Camp,David L. Rimm,Amanda Psyrri +10 more
TL;DR: A novel classification scheme that may have value for patient stratification for clinical trials testing HPV-targeted therapies is defined, namely HPV+/p16 high (class III) in oropharyngeal squamous cell carcinoma.